FDAnews
www.fdanews.com/articles/207007-sense-biodetection-receives-ce-mark-for-its-veros-covid-19-test

Sense Biodetection Receives CE Mark for Its Veros COVID-19 Test

March 17, 2022

Sense Biodetection has received a CE mark for its Veros COVID-19 test, a molecular diagnostic test that the company says provides laboratory-quality results in 15 minutes.

Sense said the test has been shown to be more than 1,000 times more sensitive than widely used antigen tests and that it can detect all variants of interest and concern identified to date by the World Health Organization.

The test, which uses nasal swabs from about 0.75 inches inside the nose, is intended for use in hospital emergency departments, pharmacies, care homes and urgent care facilities.

The company said it will begin marketing the Veros COVID-19 test in Europe by the end of March.

View today's stories